Brad Vale has been with US-based healthcare company Johnson & Johnson’s corporate venturing unit Johnson & Johnson Development Corporation (JJDC) since 1992.
In 1997 he moved to California to establish its Silicon Valley office. He has invested in more than 30 companies. Five of these were acquired by Johnson & Johnson subsidiaries.
In 2008, Vale was made head of venture investments and, in December, he took over as head of JJDC from Roy Davis to push through a reorganisation of Johnson & Johnson’s innovation strategy with an integration of its early-stage Redscript Ventures and Corporate Office of Science and Technology (Cosat) teams and expansion of innovation centres to the UK and China. He is based in Silicon Valley, California.
Vale’s boardroom seats include Neuropace and Guided Delivery Systems.
Before joining JJDC, he previously supported Johnson & Johnson’s medical device businesses at Cosat. From 1982 to 1989, he was at Ethicon, a Johnson & Johnson subsidiary.
Vale received a PhD in biomedical engineering from Iowa State University and is a Washington State University doctor of veterinary medicine.